Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Active-controlled, Randomized, Double blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab of Enzene Biosciences Limited versus Innovator Denosumab in the Treatment of Postmenopausal Osteoporosis

Next Previous
Trial Profile

A Prospective, Active-controlled, Randomized, Double blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab of Enzene Biosciences Limited versus Innovator Denosumab in the Treatment of Postmenopausal Osteoporosis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Alkem Laboratories; Enzene Biosciences

Most Recent Events

  • 10 Jan 2020 Status changed from recruiting to active, no longer recruiting.
  • 13 Nov 2018 New trial record
  • 12 Nov 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top